LU92550I2 - Lurasidone, facultativement sous forme de sa base libre ou de ses sels pharmaceutiquement acceptables - Google Patents

Lurasidone, facultativement sous forme de sa base libre ou de ses sels pharmaceutiquement acceptables Download PDF

Info

Publication number
LU92550I2
LU92550I2 LU92550C LU92550C LU92550I2 LU 92550 I2 LU92550 I2 LU 92550I2 LU 92550 C LU92550 C LU 92550C LU 92550 C LU92550 C LU 92550C LU 92550 I2 LU92550 I2 LU 92550I2
Authority
LU
Luxembourg
Prior art keywords
lurasidone
optionally
pharmaceutically acceptable
acceptable salts
free base
Prior art date
Application number
LU92550C
Other languages
English (en)
Original Assignee
Sumitomo Dainippon Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37452103&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92550(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sumitomo Dainippon Pharma Co Ltd filed Critical Sumitomo Dainippon Pharma Co Ltd
Publication of LU92550I2 publication Critical patent/LU92550I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
LU92550C 2005-05-26 2014-09-18 Lurasidone, facultativement sous forme de sa base libre ou de ses sels pharmaceutiquement acceptables LU92550I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2005153508 2005-05-26

Publications (1)

Publication Number Publication Date
LU92550I2 true LU92550I2 (fr) 2015-11-02

Family

ID=37452103

Family Applications (1)

Application Number Title Priority Date Filing Date
LU92550C LU92550I2 (fr) 2005-05-26 2014-09-18 Lurasidone, facultativement sous forme de sa base libre ou de ses sels pharmaceutiquement acceptables

Country Status (22)

Country Link
US (5) US8729085B2 (fr)
EP (2) EP1884242B1 (fr)
JP (2) JP4733120B2 (fr)
KR (2) KR101380088B1 (fr)
CN (2) CN102048734B (fr)
AU (1) AU2006250340C1 (fr)
BE (1) BE2014C057I2 (fr)
BR (2) BRPI0611409B8 (fr)
CA (1) CA2606510C (fr)
CY (2) CY1114118T1 (fr)
DK (2) DK1884242T3 (fr)
ES (2) ES2408687T3 (fr)
FR (1) FR14C0069I2 (fr)
HU (1) HUS1400051I1 (fr)
LU (1) LU92550I2 (fr)
MX (1) MX2007014872A (fr)
NL (1) NL300690I2 (fr)
PL (1) PL1884242T3 (fr)
PT (1) PT1884242E (fr)
RU (1) RU2398586C3 (fr)
SI (1) SI1884242T1 (fr)
WO (1) WO2006126681A1 (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1886678B1 (fr) * 2005-05-18 2017-04-19 Sumitomo Dainippon Pharma Co., Ltd. Comprimé stable contenant de la droxidopa
SI1884242T1 (sl) 2005-05-26 2013-07-31 Dainippon Sumitomo Pharma Co., Ltd. Farmacevtski sestavek, ki vsebuje lurazidon
CN101945657B (zh) * 2008-02-11 2015-04-22 大日本住友制药株式会社 具有改善的溶出性的片剂
KR101618388B1 (ko) 2008-06-13 2016-05-04 다이닛본 스미토모 세이야꾸 가부시끼가이샤 구강 내 급속 붕해 정제 및 이의 제조 방법
CN102170912A (zh) * 2008-09-30 2011-08-31 大洋药品工业株式会社 压缩成型制剂及其制造方法
EP2391355B1 (fr) 2009-05-19 2017-01-18 Celgene Corporation Préparations de 4-amino-2-(2,6-dioxopipéridine-3-yl)isoindoline-1,3-dione
JP5893616B2 (ja) 2010-10-18 2016-03-23 大日本住友製薬株式会社 注射用徐放性製剤
WO2012063246A1 (fr) * 2010-11-11 2012-05-18 Mapi Pharma Ltd. Forme amorphe du chlorhydrate de lurasidone
WO2012107890A2 (fr) * 2011-02-10 2012-08-16 Ranbaxy Laboratories Limited Formes cristallines de chlorhydrate de lurasidone
WO2012156981A1 (fr) 2011-05-13 2012-11-22 Cadila Healthcare Limited Compositions pharmaceutiques de lurasidone
US8981095B2 (en) 2011-07-28 2015-03-17 Mapi Pharma Ltd. Intermediate compounds and process for the preparation of lurasidone and salts thereof
CN102911169B (zh) * 2011-08-02 2015-05-06 上海医药工业研究院 一种卢拉西酮的制备方法
US20140243383A1 (en) 2011-08-24 2014-08-28 Cadila Healthcare Limited Pharmaceutical compositions of silodosin
CN103446071B (zh) * 2012-05-29 2017-12-19 江苏豪森药业集团有限公司 一种口服片剂及其制备方法和用途
CN102688209A (zh) * 2012-06-21 2012-09-26 李兴惠 鲁拉西酮片和制备方法
CN102688210A (zh) * 2012-06-21 2012-09-26 李兴惠 鲁拉西酮的药物组合物和制备方法
CN103536568B (zh) * 2012-07-12 2016-12-07 成都康弘药业集团股份有限公司 一种含有鲁拉西酮的口腔崩解片及其制备方法
CN103006661B (zh) * 2012-12-06 2015-02-18 江苏先声药物研究有限公司 一种含有盐酸鲁拉西酮的制剂及其制备方法
US20150157628A1 (en) * 2013-12-11 2015-06-11 Saravanan Kannusamy Pharmaceutical compositions of Lurasidone and Process for preparation thereof
WO2016012898A1 (fr) 2014-07-25 2016-01-28 Lupin Limited Composition pharmaceutique orale de lurasidone
CN104606133A (zh) * 2015-01-07 2015-05-13 万特制药(海南)有限公司 鲁拉西酮口服混悬液及其制备方法
WO2016139683A2 (fr) * 2015-03-05 2016-09-09 Jubilant Generics Limited Compositions pharmaceutiques de lurasidone et son procédé de préparation
DE102016205950A1 (de) * 2016-04-08 2017-10-12 Dietrich Seidel Mittel zur Verwendung bei entzündlichen Zuständen der Schleimhäute
WO2018083117A1 (fr) * 2016-11-02 2018-05-11 Sanovel Ilac Sanayi Ve Ticaret A.S. Compositions pharmaceutiques orales solides de chlorhydrate de lurasidone
CN108567758A (zh) * 2017-03-08 2018-09-25 湖南洞庭药业股份有限公司 盐酸鲁拉西酮片剂及其制备方法
CN111698992A (zh) * 2017-08-18 2020-09-22 艾伯维公司 用于治疗子宫内膜异位症、子宫肌瘤、多囊卵巢综合症或子宫腺肌症的药物配制物
CN107875122A (zh) * 2017-12-17 2018-04-06 佛山市弘泰药物研发有限公司 一种盐酸鲁拉西酮自微乳制剂及其制备方法
CN107854445A (zh) * 2017-12-17 2018-03-30 佛山市弘泰药物研发有限公司 一种盐酸鲁拉西酮分散片及其制备方法
CN107854446A (zh) * 2017-12-19 2018-03-30 佛山市弘泰药物研发有限公司 一种盐酸鲁拉西酮口崩片及其制备方法
JPWO2019167978A1 (ja) 2018-02-28 2021-02-04 大日本住友製薬株式会社 溶出が制御された水性懸濁型医薬製剤
WO2019197463A1 (fr) 2018-04-10 2019-10-17 Z-Catering Mitte Gmbh Procédé de conservation d'un plat à préparer chaud et de préparation d'aliments pour collectivité
WO2019199134A1 (fr) * 2018-04-13 2019-10-17 주식회사 삼양바이오팜 Composition pharmaceutique comprenant du lénalidomide
US20230016901A1 (en) * 2019-09-25 2023-01-19 Nobelpharma Co., Ltd. Granule in which unpleasant taste is masked and method for producing granule
CN115843243B (zh) * 2020-08-26 2025-09-05 浙江华海药业股份有限公司 盐酸鲁拉西酮组合物及其制备方法
AT17300U3 (de) * 2020-12-03 2022-02-15 G L Pharma Gmbh Feste orale pharmazeutische Zusammensetzung
KR20230124655A (ko) 2020-12-23 2023-08-25 스미토모 파마 가부시키가이샤 경구 고형 제제

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4600579A (en) * 1983-06-07 1986-07-15 Mallinckrodt, Inc. N-acetyl-p-aminophenol compositions containing partially gelatinized starch and method for preparing same
US4551177A (en) 1984-04-23 1985-11-05 National Starch And Chemical Corporation Compressible starches as binders for tablets or capsules
US4609675A (en) 1984-08-17 1986-09-02 The Upjohn Company Stable, high dose, high bulk density ibuprofen granulations for tablet and capsule manufacturing
US4837031A (en) 1987-09-17 1989-06-06 Mallinckrodt, Inc. Compositions containing ibuprofen
US5047246A (en) 1988-09-09 1991-09-10 Bristol-Myers Company Direct compression cyclophosphamide tablet
US5104648A (en) 1989-02-02 1992-04-14 Mallinckrodt Specialty Chemicals Company High ibuprofen content granulations
US4911921A (en) 1989-02-02 1990-03-27 Mallinckrodt, Inc. High ibuprofen content granulations
JP2800953B2 (ja) * 1990-07-06 1998-09-21 住友製薬株式会社 新規なイミド誘導体
US5605889A (en) 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
AU701042B2 (en) 1995-02-28 1999-01-21 Aventisub Llc Pharmaceutical composition for piperidinoalkanol compounds
JP4022269B2 (ja) * 1995-05-26 2007-12-12 協和醗酵工業株式会社 医薬組成物
PL191533B1 (pl) 1997-10-20 2006-06-30 Dainippon Sumitomo Pharma Co Szybko-rozpuszczalna kompozycja farmaceutyczna
JP4063386B2 (ja) * 1998-01-29 2008-03-19 キッセイ薬品工業株式会社 速放性経口医薬品組成物
US6150366A (en) 1998-06-15 2000-11-21 Pfizer Inc. Ziprasidone formulations
ES2688273T3 (es) * 1999-03-31 2018-10-31 Janssen Pharmaceutica Nv Almidón pregelatinizado en una formulación de liberación controlada
US6586617B1 (en) 1999-04-28 2003-07-01 Sumitomo Chemical Takeda Agro Company, Limited Sulfonamide derivatives
AU2001246861A1 (en) * 2000-04-10 2001-10-23 Sumitomo Pharmaceuticals Co. Ltd. Sustained release preparations
JP4868695B2 (ja) 2000-09-22 2012-02-01 大日本住友製薬株式会社 崩壊性が良好な経口製剤
TWI258469B (en) 2001-03-19 2006-07-21 Dainippon Pharmaceutical Co Aryl-substituted alicyclic compounds and pharmaceutical composition containing the same
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
JP4745661B2 (ja) * 2002-08-22 2011-08-10 大日本住友製薬株式会社 統合失調症治療剤
US20040186105A1 (en) 2002-08-30 2004-09-23 Allenspach Carl T. Pharmaceutical composition exhibiting consistent drug release profile
JPWO2004078173A1 (ja) * 2003-02-05 2006-06-08 塩野義製薬株式会社 溶出性の改善された錠剤
HUE044822T2 (hu) 2003-09-12 2019-11-28 Amgen Inc Cinakalcet HCl gyors feloldódású készítménye
US8153161B2 (en) 2003-12-09 2012-04-10 Dainippon Sumitomo Pharma Co., Ltd. Medicament-containing particle and a solid preparation containing the particle
WO2006096439A2 (fr) 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Compositions pharmaceutiques destinees au traitement et/ou a la prevention de la schizophrenie et de maladies associees
SI1884242T1 (sl) * 2005-05-26 2013-07-31 Dainippon Sumitomo Pharma Co., Ltd. Farmacevtski sestavek, ki vsebuje lurazidon

Also Published As

Publication number Publication date
BRPI0611409B8 (pt) 2021-05-25
EP2422783B1 (fr) 2015-04-08
US8883794B2 (en) 2014-11-11
US20140235651A1 (en) 2014-08-21
BE2014C057I2 (fr) 2025-12-10
BRPI0611409A8 (pt) 2015-12-15
AU2006250340C1 (en) 2014-06-12
CN101184489A (zh) 2008-05-21
US9555027B2 (en) 2017-01-31
RU2398586C2 (ru) 2010-09-10
RU2007148997A (ru) 2009-07-10
EP2422783A1 (fr) 2012-02-29
RU2398586C3 (ru) 2017-10-04
KR20130122019A (ko) 2013-11-06
BR122020005056A2 (fr) 2010-11-23
FR14C0069I2 (fr) 2015-11-20
CY1114118T1 (el) 2016-06-22
EP1884242B1 (fr) 2013-04-17
ES2408687T3 (es) 2013-06-21
BR122020005056A8 (pt) 2022-11-22
ES2535478T3 (es) 2015-05-12
EP1884242A4 (fr) 2009-07-01
EP1884242A1 (fr) 2008-02-06
JPWO2006126681A1 (ja) 2008-12-25
JP5285105B2 (ja) 2013-09-11
DK2422783T3 (en) 2015-05-11
PL1884242T3 (pl) 2013-09-30
US8729085B2 (en) 2014-05-20
FR14C0069I1 (fr) 2014-10-24
US20150265611A1 (en) 2015-09-24
US20090143404A1 (en) 2009-06-04
BR122020005056B1 (pt) 2023-01-10
DK1884242T3 (da) 2013-05-06
US20180161322A1 (en) 2018-06-14
BRPI0611409B1 (pt) 2020-12-29
CN101184489B (zh) 2011-01-19
CN102048734B (zh) 2013-11-20
JP2011126915A (ja) 2011-06-30
CN102048734A (zh) 2011-05-11
WO2006126681A1 (fr) 2006-11-30
CA2606510A1 (fr) 2006-11-30
US9907794B2 (en) 2018-03-06
HK1108379A1 (en) 2008-05-09
PT1884242E (pt) 2013-05-21
CY2014039I1 (el) 2016-06-22
CY2014039I2 (el) 2016-06-22
US20150056284A1 (en) 2015-02-26
KR101380088B1 (ko) 2014-04-10
AU2006250340A1 (en) 2006-11-30
HUS1400051I1 (hu) 2016-10-28
CA2606510C (fr) 2014-07-22
AU2006250340B2 (en) 2012-02-09
JP4733120B2 (ja) 2011-07-27
MX2007014872A (es) 2008-02-15
SI1884242T1 (sl) 2013-07-31
NL300690I2 (nl) 2017-11-02
KR20080012306A (ko) 2008-02-11
KR101552033B1 (ko) 2015-09-09
BRPI0611409A2 (pt) 2010-11-23

Similar Documents

Publication Publication Date Title
LU92550I2 (fr) Lurasidone, facultativement sous forme de sa base libre ou de ses sels pharmaceutiquement acceptables
LU92035I2 (fr) Vemurafenib et les sels pharmaceutiquement acceptables de celui-ci, sous toutes les formes bénéficiant de la protection conférée par le brevet de base
FR22C1008I2 (fr) Composition immunogène
LU92200I1 (fr) Linaclotide et toute forme thérapeutique équivalente de celui-ci, protégé par le brevet de base, y compris des sels pharmaceutiquement acceptables
LU92374I2 (fr) Alogliptin sous toutes ses formes telles que protégées par le brevet de base
LU92327I2 (fr) Ponatinib sous toutes ses formes telles que protégées par le brevet de base
LU92376I2 (fr) Alogliptin sous toutes ses formes telles que protégées par le brevet de base, combiné avec pioglitazone sous toutes ses formes telles que protégées par le brevet de base
LU92595I2 (fr) Siméprévir, ou l'un de ses sels pharmaceutiquementacceptables, incluant siméprévir sodium
LU92864I2 (fr) Cobicistat ou un de ses sels pharmaceutiquement acceptables
LU92137I2 (fr) Ruxolitinib, ou un de ses sels pharmaceutiquement acceptables
EP1856123A4 (fr) Inhibiteurs de mdm2, sous forme de petites molecules et utilisations de ces derniers
PL378587A1 (pl) Sposób wytwarzania (S)-(-)-2-amino-6-n-propyloamino-4,5,6,7-tetrahydrobenzotiazolu i/lub jego soli
HRP20080447T3 (en) 7-(2-(4-(3-trifluoromethyl-phenyl)-1,2,3,6-tetrahydro-pyrid-1-yl)ethyl) isoquinoline besylate salt, preparation and therapeutic use thereof
ITBO20040561A1 (it) Macchina per la lavorazione di lamiere
FR2881048B1 (fr) Composition parfumante sous forme compactee
EP1846024A4 (fr) Mutants mycobacteriens afectant l'apoptose chez l'hôte
ITMI20051435A1 (it) Macchina per la realizzazione di capi di abbigliamento e simili
ITTO20040826A1 (it) Macchina cordonatrice-piegatrice per la realizzazione di articoli cartotecnici e di legatoria
FR2884969B1 (fr) Integration d'elements capacitifs sous forme de ceramique perovskite
ITMI20040443A1 (it) Prpcesso per la preparazione di ..15-16-17-cheto-steroidi e loro uso nella sintesi di composti farmacologicamente attivi
ITMI20040505A1 (it) Macchina per la frantumazione di bottiglie
FR2886642B1 (fr) Sels alcalino-terreux d'irbesartan et leur preparation
ITVR20030013A1 (it) Procedimento per l'ottenimento di lastre dotate di
ES1061876Y (es) Flexometro perfeccionado de uña giratoria.
ITBS20050150A1 (it) Macchina per la sublimazione